Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Meningococcal Meningitis

Meningococcal Meningitis

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Meningococcal Meningitis

55 trials tracked for Meningococcal Meningitis: 36 in phase 3 or 4 and 7 with published results. The most-cited published study has 35 citations.

55Trials tracked
36Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 4 Phase 3 32 Phase 2 18 Phase 1 1
  1. Phase 3 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older Completed · 35 cited
  2. Phase 3 Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28 Completed · 31 cited
  3. Phase 3 Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Completed · 31 cited
  4. Phase 3 Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years Completed · 24 cited
  5. Phase 3 Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers Completed · 15 cited
  6. Phase 3 RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016) Completed · 13 cited
Show 44 more trials
  1. Phase 3 Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine Completed · 3 cited
  2. Phase 4 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier Completed
  3. Phase 4 Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Completed
  4. Phase 4 A Sourcing Study to Collect Human Blood Samples From Healthy Adults Completed
  5. Phase 4 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed
  6. Phase 3 Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Completed
  7. Phase 3 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers Completed
  8. Phase 3 Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers Completed
  9. Phase 3 A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea Completed
  10. Phase 3 Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 Completed
  11. Phase 3 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults Completed
  12. Phase 3 Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects Completed
  13. Phase 3 Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers Completed
  14. Phase 3 A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years Completed
  15. Phase 3 A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years Completed
  16. Phase 3 Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine Completed
  17. Phase 3 Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 Completed
  18. Phase 3 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents Completed
  19. Phase 3 Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years Completed
  20. Phase 3 Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine Completed
  21. Phase 3 Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine Completed
  22. Phase 3 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed
  23. Phase 3 Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life Completed
  24. Phase 3 A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Completed
  25. Phase 3 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants Completed
  26. Phase 3 A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults Completed
  27. Phase 3 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults Completed
  28. Phase 3 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed
  29. Phase 3 Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 Completed
  30. Phase 3 Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years Completed
  31. Phase 2 A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents Completed
  32. Phase 2 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers Completed
  33. Phase 2 Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers Completed
  34. Phase 2 Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years Completed
  35. Phase 2 A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY Completed
  36. Phase 2 Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds Completed
  37. Phase 2 Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination Completed
  38. Phase 2 Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam Completed
  39. Phase 2 Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years Completed
  40. Phase 2 Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months. Completed
  41. Phase 2 Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older Completed
  42. Phase 2 Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines Completed
  43. Phase 2 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents Completed
  44. Phase 2 A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age Completed

Showing the 50 most-cited and recently-updated of 55 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Meningococcal Meningitis: what the trials found

Multiple quadrivalent meningococcal conjugate vaccines (MenACWY) demonstrate robust immunogenicity across age groups. In toddlers, MenACYW conjugate vaccine elicited seroresponse rates of 73.8%–91.4% against serogroups A, C, Y, and W, with higher responses in adolescents (74.0%–95.6%) compared to adults (73.5%–88.1%) 13. In children aged 2–9 years, MenACYW conjugate vaccine achieved seroresponse rates of 55.4%–95.2% and geometric mean titers (GMTs) of 17.0–238, with lower GMTs in the 2–5 year subgroup 8. Similarly, MenACWY-CRM vaccine induced hSBA ≥1:8 in 88%–99% of infants following a 4-dose schedule 20. Booster responses were durable: after Menactra booster, antibody titers ≥1:4 persisted in 67.6%–98.2% at 4 years post-vaccination 3.

For serogroup B, the recombinant multicomponent vaccines rMenB+OMV NZ and rLP2086 show high immunogenicity. After a 2-dose primary series of rMenB+OMV NZ, 98%–100% of subjects achieved hSBA titers ≥4 or ≥5 14. Booster doses maintained seroprotection: 97%–100% of children had SBA titers ≥1:5 after a fourth dose 15. However, antibody persistence wanes: at 4 years of age, only 12%–35% of children retained SBA titers ≥1:5 after a primary series and booster 19. The rLP2086 vaccine was associated with a 1.55%–2.52% rate of serious adverse events 16.

Concomitant administration of MenACWY vaccines with other routine vaccines (e.g., Tdap, HPV) does not impair immune responses. When Tdap was given with MenACWY-CRM, anti-diphtheria and anti-tetanus concentrations ≥0.1 IU/mL were achieved in 97%–100% of subjects, similar to Tdap with placebo 21. Similarly, MenACYW conjugate vaccine administered with other pediatric vaccines resulted in 56.1%–78.5% achieving hSBA vaccine seroresponse 9.

For the clinician treating this condition

  • Quadrivalent MenACWY conjugate vaccines (e.g., MenACYW, MenACWY-CRM) provide high seroresponse rates across age groups, with adolescents showing the strongest responses.
  • Serogroup B vaccines (rMenB+OMV NZ, rLP2086) induce robust initial antibody responses, but persistence declines over years; booster doses are effective in restoring protection.
  • MenACWY vaccines can be co-administered with routine vaccines (e.g., Tdap, HPV) without compromising immunogenicity.

AI synthesis of 10 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Sequential reminders improved MenACWY coverage in unvaccinated youth and adults in Spain
Pediatrics RCT
Sequential reminders improved MenACWY coverage in unvaccinated youth and adults in Spain A Simple Two-Step Nudge Can Boost Crucial Teen Vaccination Rates
This randomized interventional study evaluated different reminder combinations for catch-up meningococcal ACWY vaccination among 66,891 unva…
A health system in Spain found that sending a physical letter followed by a text message was the most effective way to get more young people…
Apr 10, 2026